tiprankstipranks

Abeona approval does not change Krystal opportunity, says H.C. Wainwright

H.C. Wainwright keeps a Buy rating on Krystal Biotech (KRYS) with a $240 price target after Abeona Therapeutics (ABEO) announced FDA approval of Zevaskyn, an autologous cell-based therapy for treatment of adult and pediatric patients with recessive dystrophic epidermolysis bullosa. The firm does not see an immediate impact of Zevaskyn on Krystal’s Vykuvek commercial opportunity. Vykuvek remains the “differentiated opportunity, particularly with regard to cost, surface area coverage for wound healing and quality of life/convenience,” the analyst tells investors in a research note. Wainwright believes Vykuvek maintains its differentiated profile as the RDEB treatment of choice to both patients and clinicians.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue